AstraZeneca Statistics By Key Facts, Revenue, Region, R&D Expenditure, Therapy Area, Operating profit And Number Of Animals Used

Introduction

AstraZeneca Statistics: AstraZeneca, one of the top biopharmaceutical companies in the world, has also made notable developments in 2024 in such areas as oncology, cardiovascular, and respiratory developments. AstraZeneca, which is based in Cambridge, United Kingdom, has focused on R&D and strategic partnerships, which have been key to its growth and market expansion this year.

In this article, we shall discuss the key AstraZeneca statistics for the year 2024 in terms of financials, revenue streams, and regional market share, among others.

Editor’s Choice

• AstraZeneca statistics reveal that AstraZeneca’s annual revenue figures for 2024 were impressive, reaching $44 billion, reflecting a 12% increase attributed to the company’s successful oncology and respiratory portfolio.
• The company spent $8.5 billion on R&D, which is approximately 25% of revenue. This increased by 7% from the previous year, helping in pipeline expansion.
• AstraZeneca reported a net income of $6.1 billion, which is an increase of 14% driven by a growth in sales and alliances.
• Oncology products dominated the revenue, bringing in 17 billion dollars, which is 40% of the overall revenue, whereas drugs like Tagrisso, Imfinzi, and Lynparza recorded sales growth of 15%.
• Cardiovascular and renal drugs account for 10 billion dollars, which is 23% of the revenue, with Farxiga’s sales increasing by 20%, owing to the wider heart failure treatment claim.
• According to AstraZeneca statistics, Respiratory medicines made $6.5 billion, which is 15% of revenues, with Symbicort and Fasenra doing particularly well in the US and European markets.
• In terms of geographical segments, North America was the most lucrative revenue generator for AstraZeneca, valued at $15 billion (35% of revenue), an increase of 13% attributable to the increasing demand for oncology and immunology portfolios.
• AstraZeneca statistics reveal that Europe contributed revenue amounting to $11 billion (26% of revenue) and recorded an increase of 10% due to the sales of cardiovascular and respiratory drugs.
• The Asia-Pacific region generated revenue of $8 billion (18% of revenue), and 17% growth was recorded in China due to the increasing popularity of drugs for the treatment of cancer and diabetes.
• AstraZeneca earmarked $1 billion in research oncology treatment biotech partnerships, with a growing number of such collaborations on the rise by 30%.
• In addition, it also set aside $500 million in all-encompassing vaccine distribution in regions with a significant diseased burden but few effective and available interventions.
• The company’s value increased by 10% during the period as it enjoyed sales expansion and investor confidence in the company’s pipeline investment, reaching a market capitalization of $220 billion.
• AstraZeneca statistics indicate that AstraZeneca increased its dividend by 5% to $2.15 per share to its shareholders.
• Astra Zeneca’s employment statistics as of 2023 show that 35% of the company’s employees were located within Europe.
• AstraZeneca is regarded as one of the top ten pharmaceutical companies in the world, whose brand equity reached 5.6 billion dollars based on the COVID-19 vaccination developed by the company in collaboration with Oxford University.
• For instance, in 2022, the overall revenue for the pharmacy sector worldwide neared 1.5 trillion U.S. dollars.
• The drug that earns the most for the company, Farxiga, which widely helps in the management of type 2 diabetes, was the leading revenue earner for the firm in the year 2023.
• AstraZeneca statistics show that the critical product, Nexium, contributed $945 million, down from a high of $5.2 billion in 2008.
• Tagrisso ranked third after Farxiga, with sales estimated at close to 6 billion dollars due to revenue earnings.
• Sales for Vaxzevria, AstraZeneca’s vaccine for COVID-19, were also considerably reduced from $1.8 billion in 2022 to only $12 million in 2023.
• Crestor earned 1.1 billion dollars. In 2023, around 10.9 billion dollars was dedicated to R&D activities, which shows Astra Zeneca’s persistent drive towards embracing innovativeness in the business even in main segments such as cancer, heart, digestion, and in addition to infectious, nervous and air system and also inflammation.

AstraZeneca Key Facts

• Revenues for AstraZeneca, a British-Swedish biopharmaceutical company, remain on the rise, reaching approximately $44 billion in 2023 for the sixth year in a row.
• The hardest hit therapeutic area remained oncology, which accounted for over one-third of the firm’s overall revenue.
• In particular, Tagrisso, an antineoplastic agent used in the treatment of lung cancer and also one of the top-selling drugs of AstraZeneca, was responsible for earnings of $5.8 billion.
• Other top-selling drugs included Farxiga, Imfinzi, Soliris, and Symbicort. Meanwhile, it is worth noting that AstraZeneca became widely known due to its COVID-19 vaccine during 2020-2021, before which the company was not a leading vaccine manufacturer.
• Due to the pandemic, the company has decided to intensify its focus on vaccines and immunotherapy.
• In addition, AstraZeneca invests a significant part of its revenue into R&D.
• This is well known for AstraZeneca statistics that the company invests more than 20% of its revenue – in some years nearly 30% – back into research & development.
• In 2023, around €11 billion was allocated for R&D purposes, which classifies it as one of the pharmaceutical companies with quite a high R&D to revenue ratio.
• AstraZeneca has managed to create many innovative pharmaceuticals and has one of the biggest and most up-to-date R&D systems in the world.
• AstraZeneca’s COVID-19 vaccine, AZD1222, was one of the most popular vaccines in the world, with many pre-orders placed for it. This vaccine was first developed at the Jenner Institute of the University of Oxford, and in April 2020, AstraZeneca formed a partnership with Oxford in which it took charge of trials, production, advertisement, and distribution.
• The company, being socially responsible, made its vaccine available at no profit, and since it does not need to be stored in extremely low-temperature conditions, it became a vaccine that was easy to use in countries without such supply chains, many of them being developing countries.

AstraZeneca Revenue Statistics

(Reference: statista.com)

• These AstraZeneca statistics show the total revenue for AstraZeneca from the year 2006 to 2023.
• AstraZeneca plc, one of the ten largest companies in the world in prescription drug sales, is a global corporation with its base in London, UK.
• AstraZeneca deals in primary areas such as malignancies, heart and blood disorders, digestive system, infectious diseases, brain disorders, and respiratory, as well as inflammatory conditions.
• In partnership with the University of Oxford, it also created one of the world’s Covid-19 vaccines. In the year 2023, the revenue of AstraZeneca reached almost 44 billion U.S. dollars.

AstraZeneca Revenue By Region

(Reference: statista.com)

• AstraZeneca’s revenue in outsourcing countries, especially the United States, was over $19 billion in 2023 alone. This, of course, demonstrates the critical role of the American market in the overall business of the pharmaceutical giant AstraZeneca.
• However, what distinguishes AstraZeneca from many other big pharmaceutical companies is the fact that in addition to North America and Europe, such regions as the Far East, Southeast Asia, and South America also form a sizeable portion of its revenue.
• Thus, in addition to its well-established market in high-income countries, AstraZeneca has an overwhelmingly wide market in low-income regions, which has played a significant role in the diversification and enhancement of its global revenue.
• The AstraZeneca statistics presented in the evidence also show the geographical distribution of the revenue that AstraZeneca has realized between the years 2013 and 2023 to indicate the company’s wide geographical scope.

AstraZeneca R&D Expenditure

(Reference: statista.com)

• These AstraZeneca statistics show AstraZeneca’s dedication to innovation and ascertain the percentage of its revenue spent on R&D each year over the period of 2006 to 2023.
• In the year 2023, A cobalt blue 95% oxidized azobenzene crystal of 47 cm3 volume was made by investing 25% out of 100% of total revenue underwent considerable expenses in R&D, which underscores the company’s strategy when it comes to finding and creating new drugs.
• By investing a large proportion of its revenue in R&D, AstraZeneca seeks to always have a ready supply of new innovative drugs in all the various therapeutic areas, thereby protecting the long-term growth and competitiveness of the company in the pharmaceutical sector.

AstraZeneca Revenue By Therapy Area

(Reference: statista.com)

• The presented AstraZeneca statistics depict the revenues of AstraZeneca for the years 2022 and 2023 by therapeutic area with emphasis on the oncology division, which made remarkable gains over the period under review.
• In 2023 alone, revenue from the oncology division stood at an excess of $17 billion, representing available treatment for different kinds of malignancies.
• Such indicates how critical the oncology division is to AstraZeneca’s business, as it takes up a considerable share of the total revenue for the enterprise.
• This segment has contributed to the firm’s growth over the years, aided by critical oncology products in its pipeline.

AstraZeneca Operation Porfit

(Reference: statista.com)

• The existing evidence tracks the operating profit of the pharmaceutical company AstraZeneca, one of the top ten pharmaceutical companies in the world by prescription drug revenue, from 2006 to 2023.
• Operating profit hit around $8.2 billion for AstraZeneca in 2023, its highest profit since 2011.
• Operating profit includes earnings from primary business operations only and disallows interest and tax treatment.
• This recent figure further illustrates the encouraging performance and growth of AstraZeneca in its key geographies, such as oncology, respiratory, and other treatments.

AstraZeneca Product Crestor Revenue

(Reference: statista.com)

• The AstraZeneca statistics illustrate the revenue intake as well as the geographical difference in sales of Crestor, the salient cholesterol-lowering drug of AstraZeneca, from 2018 to 2023.
• Most of the revenue from the international sales of Crestor in 2023 came from emerging markets.
• This figure stands at 862 million US dollars, the highest sales figure recorded in the year.
• This shows that there is increasing market growth and demand for Crestor in the emerging markets, which is now better than it used to be in the older markets.
• The trend is consistent with Astrazeneca’s strategy of broadening the scope of its activities and sources of income to include the expanding markets.

AstraZeneca Vaccine Common Adverse Events

(Reference: statista.com)

• As of December 12, 2021, Spain had a total of 6,409 case reports of pyrexia after receiving the COVID-19 vaccine created by Oxford and AstraZeneca.
• Fever was by far the most reported adverse effect, as was the case for the Pfizer/BioNTech vaccine, followed in order of frequency by headache with about 4,700 case reports and myalgia with nearly 2,900.
• By that time, more than 9.7 million doses of the Vaxzevria (AstraZeneca) vaccine had been administered in this country.

AstraZeneca COVID-19 Vaccines Delivered Worldwide

(Reference: statista.com)

• According to AstraZeneca statistics, nearly 18% of the total number of AstraZeneca vaccines that have been distributed worldwide have been received by high-income countries and 15.9% of Upper middle-income countries.
• In stark contrast, almost two-thirds of the vaccines were given to lower-middle-income nations.
• This fact reveals the vaccination policy on AstraZeneca COVID-19 vaccines across regions as defined by country income group as of the same date.

Number Of Animals Used By AstraZeneca

(Reference: statista.com)

• AstraZeneca statistics offer insight into the number of animals used by AstraZeneca in conducting its research activities between 2006 and 2023.
• In the year 2023, the organization used roughly 123,000 animals for the company’s research activities.
• This information is indicative of the extent to which the company employs animal models during the process of developing and testing its therapeutic drugs, which is a standard practice within the pharmaceutical industry before the commencement of human trials.

Recent Developments

• In February 2024, AstraZeneca completed its takeover of Gracell Biotechnologies, Inc. (Gracell), a biotech firm that is still undergoing clinical trials to develop novel cell-based therapies for both oncological and autoimmune conditions.
• This is a strategic acquisition for AstraZeneca, which adds to its growing focus on cell therapies, especially with regard to AZD0120 (formerly dubbed GC012F), a new CAR-T therapy that is already in the clinic.
• Particularly, this one has applications in multiple myeloma and other hematologic malignancies in addition to autoimmune diseases such as systemic lupus erythematosus (SLE).
• The upfront cash payment for the acquisition was around $1.0 billion, jumping the total transaction value, including possible future payments, to about $1.2 billion if every condition is satisfied.
• In addition, upon acquisition, AstraZeneca also received Gracell’s cash and cash equivalents of $209 million as of the date of the deal.
• In the same month, AstraZeneca also finished buying Icosavax, Inc., located in the US, a clinical-stage biopharmaceutical company that harnesses a protein virus-like particle platform to create unique vaccines.
• The upfront cash consideration for this acquisition was close to $0.8 billion, and the total transaction value could be approximately $1.1 billion, which would include contingent payments that are likely to be made at the maximum possible level.
• At the closing of the transaction, AstraZeneca also gained Icosavax’s cash, cash equivalents, and marketable securities, which summed up to $192 million.
• In March 2024, AstraZeneca declared a definitive agreement to acquire Amolyt Pharma, which is a clinical-stage biotechnology company with a focus on developing therapies for rare endocrine disorders.
• The proposed acquisition seeks to advance AstraZeneca’s late-stage pipeline of drug development for rare diseases as well as strengthen its bone metabolism franchise through the addition of eneboparatide, also referred to as AZP-3601, a therapeutic investigational peptide that is under development in Phase III clinical trials and focuses on important treatment gaps in hypoparathyroidism.
• The immediate cash consideration for this purchase is $0.8 billion at closing. The overall value of the deal, including any possible future payments, is expected to be around $1.05 billion.
• AstraZeneca plans to consolidate all remaining interests in Amolyt Pharma as a cash and debt-free transaction.
• The completion of the acquisition is expected to take place on or before the third quarter of 2024, subject to normal closing conditions, including approvals from regulatory authorities.

Conclusion

In conclusion, AstraZeneca’s statistics for the year 2024 illustrate a commendable financial position, an effective product mix, and a strong presence in all geographies. The company’s dedication to research and development and collaborations gives it the necessary tools to stay at the top of the biopharma business.

Ketaki Joshi

Ketaki Joshi is a professional medical writer with extensive experience in scientific research on illness, health, and healthcare. Her work includes creating feature articles for newsletters and websites, as well as research news stories for doctors and researchers. With a lifelong passion for reading, Ketaki transitioned from a career at a French multinational company to pursue writing professionally. Her dedication to the craft has culminated in the recent release of her first Amazon-published short story, "The Envelope That Changed Our Lives."

More Posts By Ketaki Joshi

Roche Statistics By Facts, Revenue, Therapy Area, Operating Profit, R&D Expenditure, Net Income, Total Sales And Customer Area

Novartis Statistics By Facts, Market, Net Income, Full-Time Employees, R&D Projects, Dividend Paid, Capital Structure And Debt

Biofuels Statistics By Market Value, Production, Product Type, Consumption, Regions, Facts Challenges And Forecast

Dietary Sugar Statistics By Production, Age And Facts

AstraZeneca Statistics By Key Facts, Revenue, Region, R&D Expenditure, Therapy Area, Operating profit And Number Of Animals Used

GlaxoSmithKline (GSK) Statistics By Divisions, Revenue, Advertising Spending, Operating Profit, Stock Price, Patents Portfolio And Facts

Digital Health Statistics By Key Facts, Market Size, Country, Wearables and App Usage

Gluten Free Diet Statistics By Market Value, Share Of US Consumers, Types, Reasons and Product Categories

Patreon Statistics By Creators, Income and Facts

Synthetic Biology Statistics By Market Share, Revenue, Country And Technology Insights